Leslie Citrome

Nov 2, 2024 | nature.com | Amy Claxton |David P Walling |Leslie Citrome |Haiyuan Zhu |Andrew Miller |Stephen K. Brannan | +5 more

In the 5-week, randomized, double-blind, placebo-controlled EMERGENT-1 (NCT03697252), EMERGENT-2 (NCT04659161), and EMERGENT-3 (NCT04738123) trials, xanomeline and trospium chloride (formerly known as KarXT) significantly improved symptoms of schizophrenia and was generally well tolerated. We pooled data from the EMERGENT trials to further characterize the efficacy of xanomeline/trospium and provide sufficient statistical power to analyze responses in participant subgroups. In pooled analyses, xanomeline/trospium significantly improved Positive and Negative Syndrome Scale (PANSS) total score at week 5 versus placebo (least squares mean difference, –9.9; 95% confidence interval, –12.4, –7.3; p < 0.0001; Cohen’s d effect size, 0.65). PANSS subscale and Clinical Global Impression–Severity scores also improved significantly with xanomeline/trospium versus placebo. Subgroup analyses consistently favored xanomeline/trospium over placebo regardless of differences in participant age, sex, race, body mass index, and baseline PANSS total score. These results add to existing evidence demonstrating robust and reliable improvements in symptoms with xanomeline/trospium across a broad spectrum of people with schizophrenia.

Jul 24, 2024 | tandfonline.com | Justin Faden |Vanessa Martinez |Leslie Citrome |Camila Ramirez

ABSTRACTIntroduction Long-acting injectable (LAI) antipsychotic medications can help improve treatment adherence in patients with schizophrenia and bipolar disorder. Despite this, they are underutilized. In 2003, intramuscular risperidone became the first available LAI atypical antipsychotic medication, and since then, a number of competing long-acting risperidone formulations have been brought to market, with additional options under active development.

May 5, 2024 | psychiatrictimes.com | Leslie Citrome

CONFERENCE REPORTER“I’m particularly excited about muscarinic agonism as a treatment for schizophrenia because this is a new mechanism where we can actually treat the symptoms of schizophrenia, like hallucinations and delusions, without blocking dopamine D2 receptors in the striatum. This is different from what we have been doing for the past 70 years.”In this Mental Health Minute, Leslie L.

Dec 13, 2023 | jamanetwork.com | Christoph U. Correll |Leslie Citrome

Pharmacologic Treatment of Schizophrenia Beyond Dopamine Receptor Blockade—Has Its Time Come Yet?

Dec 1, 2023 | mdedge.com | Leslie Citrome

1. Rosenberg R, Citrome L, Drake CL. Advances in the treatment of chronic insomnia: a narrative review of new nonpharmacologic and pharmacologic therapies. Neuropsychiatr Dis Treat. 2021;17:2549-2566. 2. Citrome L. Dissecting clinical trials with ‘number needed to treat.’ Current Psychiatry. 2007;6(3):66-71. 3. Citrome L.